Best Supermarket Stocks To Own Right Now

Significant job gains last month in two economic bellwethers, construction and manufacturing, are raising expectations for continued strong payroll growth and a strengthening recovery next year.

Together those industries contributed 44,000 new jobs to the overall economy’s better-than-expected gain of 203,000, the Labor Department said Friday. Meanwhile, the unemployment rate fell to a five-year low of 7% from 7.3% in October.

The unemployment rate fell to a five-year low of 7% from 7.3%, the Labor Department said Friday, as federal employees furloughed during October’s government shutdown returned to work. . Un employment rose in October because the federal government furloughed about 450,000 workers during the 16-day shutdown. The jobless rate, in turn, was expected to fall in November as those employees were back at work.

Best Supermarket Stocks To Own Right Now: Unione di Banche Italiane ScpA (BPD)

Unione di Banche Italiane Scpa is an Italy-based holding company engaged in the governance, control, coordination and support of Unione di Banche Italiane Group. The Company’s activities are divided into three business segments. The Banking sector comprises of nine network banks of the Group, including IW Bank SpA, Banque de Depots et de Gestione SA and UBI International SA. The Non-banking financial sector includes Centrobanca SpA, Ubi Leasing SpA, Ubi Factor SpA, Ubi Pramerica SGR SpA, Banca 24-7 SpA, Silf SpA, Prestitalia SpA, Ubi Fiduciaria SpA and UBI Gestioni Fiduciarie SIM SpA. The Corporate Centre segment comprises UBI Banca Scpa and Ubi Sistemi e Servizi Scpa, among others. The Company is engaged in the corporate banking, consumer credit, asset management, factoring, leasing, life and non-life bancassurance sectors, among others. On May 6, 2013, it completed merger of Centrobanca Banca di Credito Finanziario e Mobiliare SpA into the Company. Advisors’ Opinion:

  • [By April Yee]

    In its annual outlook, released this month, Opec said demand for its crude would dip to between 28 million and 29.2 million barrels per day (bpd) by 2018, from 30.3 million bpd today.

  • [By Robert Rapier]

    US oil production has risen from 5 million barrels per day (BPD) in 2008 to 7.3 million BPD in the most recent quarter. The US is now the fastest-growing oil producing region in the world.

Best Supermarket Stocks To Own Right Now: Datalink Corporation(DTLK)

Datalink Corporation data center solutions and services to mid and large-size companies in the United States. It engages in assessing, designing, deploying, and supporting infrastructures, such as servers, storage, and networks; and reselling hardware and software from original equipment manufacturers. The company?s portfolio of solutions and services comprise consolidation and virtualization services; data storage and protection services, including local and remote backup, disaster recovery, archive, and compliance services; advanced network infrastructure services that includes assessment, design, and deployment of network infrastructures; and business continuity and disaster recovery solutions. It also offers a suite of practice-specific consulting, analysis, design, implementation, management, and support services. Datalink Corporation was founded in 1958 and is headquartered in Chanhassen, Minnesota.

Advisors’ Opinion:

  • [By Tess Stynes var popups = dojo.query(“.socialByline .popC”); popups.forEach(fu]

    Data-center infrastructure and services provide Datalink Corp.(DTLK) posted results for the first three months of the year that badly missed expectations and also provided an outlook for the current quarter below consensus. Shares fell 21% to $10 premarket.

  • [By Lauren Pollock]

    Datalink Corp.(DTLK), a provider of data-center infrastructure and service, boosted its fourth-quarter earnings outlook amid expectations that its revenue will be stronger than previously anticipated. Shares surged 31% to $14.20 premarket.

Best Supermarket Stocks To Own Right Now: Novartis AG (NVS)

Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholl y owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.

In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon’s portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.

Pharmaceuticals Division

The Company’s Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented pr escription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.

The Company’s Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tu mors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chron ic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.

The Company’s Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company’s Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson’s disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.

Alcon Division

The Company’s Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.

Alcon’s Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcryS of IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.

Alcon Division’s Ophthalmic Pharmaceuticals business combines Alcon’s range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division’s Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav soluti on for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.

Sandoz Division

The Company’s Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics , Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.

In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women’s health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals’ Diovan/Co-Diovan).

Vaccines and Diagnostics Division

The Company’s Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world’s blood supply. Novartis Vaccines’ products include influenza, meningococcal, pediatric, adult and travel vaccines.

The Company’s influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines includ e Polioral and Quinvaxem.

Consumer Health

Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.

OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).

Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for c ompanion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.

Advisors’ Opinion:

  • [By WWW.DAILYFINANCE.COM]

    Andrew Yates, AFP/Getty Images LONDON — The board of AstraZeneca on Monday rejected the improved $119 billion takeover offer from U.S. drugmaker Pfizer, a decision that caused a sharp slide in the U.K. company’s share price as many investors think it effectively brings an end to the protracted and increasingly bitter takeover saga. The board said in a statement that it “reiterates its confidence in AstraZeneca’s ability to deliver on its prospects as an independent, science led business.” Pfizer (PFE), which is the world’s second-biggest drugmaker by revenue, has been courting No. 8 AstraZeneca (AZN) since January, arguing their businesses are complementary. On Sunday, it raised its stock-and-cash offer by 15 percent to $118.8 billion, or 70.73 billion pounds. That would be the richest acquisition ever among drugmakers and the third-biggest in any industry, according to figures from research firm Dealogic. AstraZeneca didn’t take long to reject the new offer, its board arguing Pfizer is making “an opportunistic attempt to acquire a transformed AstraZeneca, without reflecting the value of its exciting pipeline” of experimental drugs. Because Pfizer said it won’t raise its offer again or launch a hostile takeover bid over the heads of AstraZeneca’s board, the prospect of a deal looks increasingly remote unless AstraZeneca shareholders urge a change of mind. Pfizer has said it hopes AstraZeneca’s shareholders will push for a deal. “This has been going on for quite some time and we have been in very deep engagement over the whole of the weekend,” AstraZeneca Chairman Leif Johansson told the BBC. “If Pfizer now says this is the final offer I have to believe what they say.” Shareholders in AstraZeneca seemed to think a deal is now unlikely, with the company’s share price slumping 11 percent to 43.15 pounds. Johansson said his management team had told Pfizer over the weekend that it would need to see a 10 percent improvement over the 53.50 pounds-per-shar

  • [By Brian Orelli]

    Shares of the biotech have been on a bit of a roller coaster over the last year as investors went from having high hopes for Ariad Pharmaceutical’s leukemia drug Iclusig to seeing the drug getting pulled from the market because the drug is linked to blood clots. After returning to the market, Ariad’s shares have more than doubled off their lows, but are still well off of where they were when investors thought Iclusig could compete with Novartis’ (NYSE: NVS  ) Gleevec and Bristol-Myers Squibb’s (NYSE: BMY  ) Sprycel as first-line treatments.

Best Supermarket Stocks To Own Right Now: Advance Auto Parts Inc(AAP)

Advance Auto Parts, Inc., through its subsidiaries, operates as a retailer of automotive aftermarket parts, accessories, batteries, and maintenance items. It operates in two segments, Advance Auto Parts (AAP) and Autopart International (AI). The AAP segment operates stores, which primarily offer auto parts, including alternators, batteries, chassis parts, clutches, engines and engine parts, radiators, starters, transmissions, and water pumps; accessories comprising floor mats, mirrors, vent shades, MP3 and cell phone accessories, and seat and steering wheel covers; chemicals consisting of antifreeze, freon, fuel additives, and car washes and waxes; and oil and other automotive petroleum products. This segment also provides battery and wiper installation, battery charging, check engine light reading, electrical system testing, video clinics and project brochures, loaner tool programs, and oil and battery recycling services; and sells its products through online. The AI segm ent operates stores that offer replacement parts for domestic and imported cars, and light trucks to customers in northeast and mid-Atlantic regions, as well as to warehouse distributors and jobbers in North America. As of January 1, 2011, the company operated 3,369 AAP stores, including 3,343 stores located in the northeastern, southeastern, and Midwestern regions of the United States under the Advance Auto Parts and Advance Discount Auto Parts trade names; 26 stores situated in Puerto Rico and the Virgin Islands under the Advance Auto Parts and Western Auto trade names; and 194 stores under the Autopart International trade name in the United States. It serves do-it-yourself, do-it-for-me, or commercial customers. The company was founded in 1929 and is based in Roanoke, Virginia.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of AutoZone have fallen 1.7% to $531.87 at 11:52 a.m., while Advance Auto Part (AAP) has dropped 1.6% to $121.27 and O’Reilly Automotive (ORLY) has declined 0.9% to $147.25. Pep Boys (PBY), however, has bucked the selling–its shares have gained 1.9% to $10.57.

  • [By Peter Graham]

    The fiscal Q3 2014 earnings report for auto parts retailer stock AutoZone, Inc (NYSE: AZO), a peer of Advance Auto Parts, Inc (NYSE: AAP), O’Reilly Automotive Inc (NASDAQ: ORLY) and The Pep Boys – Manny, Moe & Jack (NYSE: PBY), is scheduled for before the market opens on Tuesday. Aside from the AutoZone earnings report, it should be said that Advance Auto Parts, Inc reported Q1 2014 earnings on May 15th (results were better than expected and they upped guidance); O’Reilly Automotive Inc reported Q1 2014 earnings on April 24th (results topped expectations); and The Pep Boys reported Q4 2013 earnings on April 15th and will report Q1 2014 earnings on June 10th (PBY reported a surprise loss as tire pricing negatively hit revenue). However and given the current uncertain economy that is keeping most consumers in their old cars, you would think that auto parts retailers in general would all be doing well.

Best Supermarket Stocks To Own Right Now: Bluforest Inc (BLUF)

Bluforest Inc., formerly Greenwood Gold Resources, Inc., incorporated on March 26, 2008, is a carbon offset credit trading company with land assets in South America. Global Environmental Investments Limited (GEIL) sold all of the rights and interests held by GEIL pursuant to the Acquisition Agreement, on March 30, 2012, to the Company regarding the Property, which consists of approximately 105,000 hectares. It consists of 100% of GEIL’s rights, title and interests in and to the timber, minerals, substances and the rights to receive from the Property, and 100% of the right, title and interests of GEIL in all existing oil, gas and/or mineral unitization, pooling and/or communization agreements, declarations, and/or orders and the properties covered or included in the units, which relate to the Property.

The Property consists of 100% of the right, title and interests of GEIL in all existing and agreements, including sales and sales related contracts, operating agreements and other agreements and contracts, which relate to Fundacion Nelson Velasco Aguirre (NVA), the Property or which relate to the exploration, development, operation or maintenance of the Property or the treatment, storage, transaction or marketing of production from or allocated to the Property. The 105,000 hectares also consists of 100% of the right, title and interests of GEIL in and to all materials, supplies, machinery, equipment, improvements, and other personal property and fixtures relating to the Property, and all wells, wellhead equipment, pumping units, flow lines, tanks, buildings, injection facilities, salt water disposal facilities, compression facilities, gathering systems and other equipment, all easements, rights-of-way, surface leases and other surface rights, all permits and licenses and all other appurtenances, used or held for use in connection with or related to the exploration, development, operation or maintenance of any of the Property.

Advisors’ Opinion:

  • [By Peter Graham]

    What’s the Catch With Multi-Corp International Inc? According to various disclosures, no transactions have occurred to mention Multi-Corp International in various investment newsletters. Moreover, I am not seeing any recent news on the newswires about the company with the latest press release dating from late July about the posting of a blanket bond. However and as I noted in an earlier about BluForest Inc (OTCMKTS: BLUF), the company has been named in a Freedom of Information request with the SEC by George Sharp (of Pumps&Dumps.com) for all complaints filed against Jim Can. George apparently contends that Jim controls BluForest along with Multi-Corp International, but the former has recently won an injunction against the latter for “alleged, completely false, defamatory claims and statements.” Otherwise, investors should be aware that Multi-Corp International’s most recent financials date from the end of September of last year – meaning its inves tor beware until they get current.

  • [By Peter Graham]

    Small cap stocks BluForest Inc (OTCMKTS: BLUF), Dephasium Corp (OTCMKTS: DPHS) and IceWEB, Inc (OTCBB: IWEB) have been getting some attention for at least a few weeks now thanks to paid for promotional activity. Of course, there is nothing wrong with properly disclosed stock promotions, but one of these stocks also has a former shareholder who has filed a civil action against it alleging there is an illegal “pump and dump” scheme going on. So what’s the whole story and more importantly, what will happen with these small cap stocks when the well from promoters eventually goes dry? Here is a closer look and a quick reality check:

Best Supermarket Stocks To Own Right Now: Cytec Industries Inc (CYT)

Cytec Industries Inc/De/, formerly Cytec Industries Inc., incorporated on December 17, 1993, is a specialty chemicals and materials company focused on developing, manufacturing and selling value-added products. Its products serve a diverse range of end markets, including aerospace and industrial materials, mining and plastics. The Company has four business segments: Engineered Materials, Umeco, In-Process Separation and Additive Technologies. Engineered Materials segment principally includes advanced composites, carbon fiber, and structural film adhesives. The Umeco segment includes composite and process materials, primarily for the aerospace and defense, wind energy, automotive, recreation and other industrial segments. The In Process Separation segment includes mining chemicals and phosphines. The Additive Technologies segment includes polymer additives, specialty additives and formulated resins. On July 20, 2012, the Company acquired Umeco plc.

Engineered Materials

The Engineered Materials segment is a global provider of technologically advanced materials for aerospace, high-performance industrial and other extreme-demand markets. Its primary product lines are advanced aerospace composites and structural adhesives, High performance industrial materials and Carbon fibers. Its major products in the advanced aerospace composites include aerospace- qualified prepregs, resin infusion systems and structural/surfacing adhesives. Its principal applications include commercial airliners, regional and business jets, military aircraft, including rotorcraft, satellites and launch vehicles. The products in the high performance industrial materials include Industrial-grade prepregs, resin infusion systems and structural/surfacing adhesives. Its applications include high performance automotive, defense, tooling and alternative energy. The products in carbon fibers include high performance fiber carbon fibers. Its applications in clude reinforcements for advanced aerospace and industrial c! omposites.

The Company is a supplier to the F-35 Joint Strike Fighter and F-18 fighter jet programs. It is also a supplier for the business and regional jet market, supporting programs, such as Bombardier’s CSeries and LearJet85. It also manufactures specialty adhesive forms for complex composites assemblies, such as honeycomb and sandwich structures and special surfacing films to provide aircraft lightning strike protection. It manufactures and sells various high-performance grades of both polyacrylonitrile (PAN) type and pitch type carbon fibers used as a reinforcement material for aerospace and other extreme-demand and high-performance composites.

The Company’s High Performance Industrial Materials (HPIM) product line strategy is to leverage its composites, adhesives and resin technologies across multiple industrial markets. The Company supplies composites and adhesives to a spectrum of markets, such as high performance and luxury low-rate s erial automotive, defense, and alternative energy.

Umeco

Umeco’s primary product lines are High performance composites structural materials/solutions and Composite process materials/solutions. Its major products in the High performance composites structural materials/solutions include Aerospace-qualified prepregs, Industrial-grade prepreg. Its principal applications include large commercial airliners, military aircraft, high performance automotive, defense, tooling, recreation, industrial and alternative energy. The products in Composite process materials/solutions include Process materials/solutions including vacuum bagging, release films and sealant tapes. Its principal applications include large commercial airliners, military aircraft, high performance automotive, defense, tooling, recreation, industrial and alternative energy and Process materials for the forming, infusion, curing of composite structures.

The Company’s struct ural materials product line includes the development, manufa! cturing a! nd supply of advanced composite materials. It specializes in the manufacture of composite materials for a range of industries such as aerospace and defense, marine, motor sport and automotive, construction, wind energy, and recreation.

In-Process Separation

The In-Process Separation segment includes mining chemicals and phosphines. The Company’s mining chemicals product line include flotation promoters, collectors, frothers, dispersants and depressants, solvent extractants, flocculants, filter and dewatering aids, antiscalants, and defoamers . Its principal applications include mineral separation and processing for copper, alumina, cobalt, nickel, and other minerals. Its Phosphines include flame retardants, catalyst ligands, high purity phosphine gas and biocides.

Its phospine based specialty products are used primarily in the pharmaceutical, chemical and electronic manufacturing, and fumigation. Its patented MaxHT antiscalant is so ld for suppressing sodalite scale formation. Its phosphine specialties are utilized for a variety of applications. It is a supplier of ultra- high purity phosphine gas, used in semiconductor manufacturing and light emitting diode applications, various phosphine derivative products, including phosphonium salts used in pharmaceutical catalysts and biocides. Included in the phosphine line are organo phosphorus compounds. The compounds are used primarily as intermediates and catalyst ligands for organic and chemical synthesis in the pharmaceutical and chemical industries.

Additive Technologies

The Additive Technologies segment includes polymer additives specialty additives and Formulated resins. Polymer additives include ultraviolet light stabilizers and absorbers, high performance antioxidants and antistatic agents. Its applications include plastics, coatings, and fibers for: agricultural films, automotive parts, architectural lighting, housewares, pac kaging, outdoor furniture, sporting goods, toys and apparel.! Specialt! y additives include surfactants, specialty monomers, resin amines, and PTZ Phenothiazine. Its Formulated resins are used in for bonding or sealing of electrical and electronic components.

The Company markets its Additive Technologies chemicals through specialized sales and technical service staffs for each of its product lines. Sales are usually made directly to customers and through distributors to smaller customers. The Company is a global supplier to the plastics industry of specialty additives, which protect plastics from the ultraviolet radiation of sunlight and from oxidation. It is a global supplier of sulfosuccinate surfactants, Docusate sodium, and PTZ phenothiazine. Sulfosuccinate surfactants and acrylamide-based specialty monomers products are used in emulsion polymers, paints, paper coatings, printing inks, and other diverse customer applications. Docusate is a pharmaceutical grade product used as both an active ingredient and excipient/formulating a id. PTZ phenothiazine is primarily used as an acrylic acid, acrylic ester and methacrylate monomer stabilizer.

Advisors’ Opinion:

  • [By Stoyan Bojinov]

    The New Jersey-based specialty chemicals maker, Cytec Industries (CYT), announced third quarter operating results after the closing bell on Thursday that topped analysts’ estimates.

    Cytec Industries managed to rake in revenues of $464 million last quarter, falling short of the projected $482.61 million figure. The company did manage to beat the mark, however, in terms of earnings per share; in the third quarter Cytec generated EPS of $1.32, beating the expected EPS of $1.34 by two pennies.

    Looking back, the most recent quarterly results are well above the 91 cents EPS seen in Q3 exactly one year ago. Looking ahead, the company expects FY2013 EPS of $4.70-$4.80 compared to the consensus of $4.82.

    Cytec Industries shares rallied higher on Thursday, gaining 0.58% on the day. The stock is up 25% YTD.

  • [By Rich Duprey]

    Specialty chemicals and materials maker Cytec Industries  (NYSE: CYT  ) announced this morning that it will be completing its previously authorized $650 million share repurchase program that it had announced last October, and the board of directors has authorized a new $200 million buyback plan.

Best Supermarket Stocks To Own Right Now: National Australia Bank Ltd (NAUBF)

National Australia Bank Limited is a financial services organization providing products, advice and services through its major Australian franchise and businesses. The Company’s segment includes Business Banking, Personal Banking, Wholesale Banking, UK Banking and NZ Banking, MLC and NAB, Great Western Bank (GWB), the Corporate Functions and Other segment. MLC is the wealth management division of the National Australia Bank (NAB). In January 2014, Sandfire Resources NL announced that National Australia Bank Limited and its associated entities have ceased to be the substantial holder of the Company. In January 2014, Commonwealth Property Office Fund announced that National Australia Bank Ltd and its associated entities have ceased to be a substantial shareholder in Commonwealth Property Office Fund. In February 2014, Fairfax Media Ltd announced that National Australia Bank Ltd and its associated entities ceased holding interest in the capital of the Company. Advisors’ Opinion:

  • [By MARKETWATCH]

    LOS ANGELES (MarketWatch) — Australia stocks enjoyed early Monday gains after an advance for commodities and U.S. stocks since the last session, with a relatively good reception for earnings. The S&P/ASX 200 (AU:XJO) improved by 0.4% to 5,376.30, with miners tracking gains in gold and copper. Rio Tinto Ltd. (AU:RIO) (RIO) added 1.3%, and Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) traded 1.1% higher, while gold miners Newcrest Mining Ltd. (AU:NCM) (NCMGF) and Kingsgate Consolidated Ltd. (AU:KCN) (KSKGF) rallied 2.2% and 4.7%, respectively. Banks rose after Wall Street shares climbed on Friday, with National Australia Bank Ltd. (AU:NAB) (NAUBF) up 1% and Australia & New Zealand Banking Group (AU:ANZ) (ANEWF) adding 0.9%, though Commonwealth Bank of Australia (AU:CBA) (CBAUF) dropped 2.4% as it traded without rights to its latest dividend. Coal transport firm Aurizon Holdings Ltd. (AU:AZJ) (QRNNF) tacked on 2.1% as its fiscal first-half underlying profit increased 18%, though net profit f

  • [By MARKETWATCH]

    LOS ANGELES (MarketWatch) — Australian stocks started Monday trade higher, with the S&P/ASX 200 (AU:XJO) up 0.8% at 5,206.40 after a strong finish for Wall Street at the end of last week. Resource shares got a lift from gains for commodities prices since the previous trading session, with strong advances for gold and copper and a more than 2% rise for New York-traded crude-oil futures. Among the leading gainers, Rio Tinto Ltd. (AU:RIO) (RIO) added 1.2%, Oil Search Ltd. (AU:OSH) (OISHF) climbed 1.3%, and gold miners Newcrest Mining Ltd. (AU:NCM) (NCMGF) and Evolution Mining Ltd. (AU:EVN) (CAHPF) improved by 3.9% and 6.4%, respectively. The heavily weighted banking sector also enjoyed solid gains, with Commonwealth Bank of Australia (AU:CBA) (CBAUF) up 1%, Westpac Banking Corp. (AU:WBC) (WEBNF) trading 1.3% higher, and National Australia Bank Ltd. (AU:NAB) (NAUBF) rising 1.1% as the U.K.’s Sunday Times reported the lender is considering a £2 billion ($3.3 billion) float of its British operations, which the report said had dragged on NAB’s results in recent years.

  • [By MARKETWATCH]

    LOS ANGELES (MarketWatch) — Australian stocks inched lower in early Friday trade, with the S&P/ASX 200 (AU:XJO) down 0.1% at 5,322.00, with weakness in miners outweighing mild strength in financials. Shares of BHP Billiton Ltd. (AU:BHP) (BHP) and Rio Tinto Ltd. (AU:RIO) (RIO) fell 1.4% apiece, while Fortescue Metals Group Ltd. (AU:FMG) (FSUMF) lost 2.2% and gold miner Evolution Mining Ltd. (AU:EVN) (CAHPF) lost 0.8%, after copper prices fell to two-week lows and Chinese steel futures also lost ground, according to Reuters. The sector could react to Chinese trade data due out later in the day, as China remains a top market for Australian commodities. Stock in Alumina Ltd. (AU:AWC) (AWCMF) retreated 2.6% after its U.S. partner Alcoa Inc. (AA) posted a quarterly loss. On the upside, the big four banks all traded higher, with Commonwealth Bank of Australia (AU:CBA) (CBAUF) up 0.1%, National Australia Bank Ltd. (AU:NAB) (NAUBF) rising 0.2%, Westpac Banking Corp. (AU:WBC) (WEBN

Best Supermarket Stocks To Own Right Now: Hemispherx Biopharma Inc (HEB)

Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.The commercial focus for Ampligen includes application as a treatment for Chronic Fatigue Syndrome (CFS) and as an influenza vaccine enhancer (adjuvant) for both therapeutic and preventative vaccine development. Alferon N Injection is a United States Food and Drug Administration (FDA) approved product with an indication for refractory or recurring genital warts. Alferon LDO (Low Dose Oral) is a formulation under development targeting influenza. It has three subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp. The Company’s foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A.

Ampligen

Ampligen is an experimental drug, which is undergoing clinical development for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Over 1,000 patients have participated in the Ampligen clinical trials representing the administration of more than 90,000 doses of this drug. The Company is also engaged in ongoing, experimental studies assessing the efficacy of Ampligen against influenza viruses.

Alferon N Injection

Alferon N Injection is the registered trademark for the Company’s injectable formulation of natural alpha interferon. Interferons are a group of proteins produced and secreted by cells to combat diseases. The Company’s natural alpha interferon is produced from human white blood cells. Alferon N Injection [Interferon alfa-n3 (human leukocyte derived)] is a highly purified, natural-source, glycosylated, multi-species alpha interferon product.

Alferon LDO (Low Dose Oral)

Alferon LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)]! is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon and like Alferon N Injection should not cause antibody formation, which is a problem with recombinant interferon. It is an experimental immunotherapeutic that works by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa.

The Company competes with Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Baxter International, Fletcher/CSI, AVANT Immunotherapeutics, AVI BioPharma and Genta.

Advisors’ Opinion:

  • [By MONEYMORNING]

    Hemispherix Biopharma Inc. (NYSE: HEB) is a specialty pharmaceutical company. It engages in the clinical development of new drug therapies based on natural immune system enhancing technologies and targets the treatment of viral and immune-based clinical disorders. The Philadelphia, Pa.-headquartered company gained widespread attention over the last several months for its work on flu research. Its flagship products include Alferon N Injection, approved by the FDA for a category of sexually transmitted disease infection. Experimental treatments include Ampligen and Oragens, in development stages for the potential treatment of global viral diseases and disorders of the immune system including human papilloma virus, human immunodeficiency virus, chronic fatigue syndrome, hepatitis, and influenza. Shares have traded as low as $0.18 and as high as $0.55 over the last year. At last check, shares were changing hands around $0.50 on volume of 2 million shares.

Best Supermarket Stocks To Own Right Now: Take-Two Interactive Software Inc.(TTWO)

Take-Two Interactive Software, Inc. publishes, develops, and distributes interactive entertainment software, hardware, and accessories worldwide. The company develops and publishes software titles for various gaming and entertainment hardware platforms, including PlayStation3 and PlayStation2 computer entertainment systems, PlayStation Portable system, Xbox 360 video game and entertainment system, and Wii and DS systems, as well as for the personal computer and games for Windows. It offers products through its wholly owned labels Rockstar Games and 2K, which publishes titles under 2K Games, 2K Sports, and 2K Play. The company, through its subsidiary, Jack of All Games, also distributes software, hardware, and accessories in North America. Its proprietary brand franchises include Grand Theft Auto; Sid Meier’s Civilization; Max Payne; Midnight Club; Manhunt; Red Dead Revolver; Bully; BioShock; Sid Meier’s Railroads!; Sid Meier’s Pirates!; Carnival Games; and Top Spin, as wel l as licensed brands comprise the sports games Major League Baseball 2K; NBA 2K; and NHL 2K. The company sells its software titles to retail outlets through direct relationships with large retail customers and third party distributors. Its customers include mass merchandisers, specialty retailers, video stores, electronics stores, toy stores, national and regional drug stores, and supermarket and discount store chains. The company was founded in 1993 and is headquartered in New York, New York.

Advisors’ Opinion:

  • [By WWW.DAILYFINANCE.COM]

    www.take2games.com Sometimes, the right answer when a potential suitor appears before you on bended knee is “Yes.” But there’s been no shortage of attractive offers getting spurned on Wall Street. Sometimes those offers just don’t make sense: Boards aren’t ready to sell; shareholders think their stock is worth more, and vote down the deals. AstraZeneca (AZN) recently became the latest big company to refuse a suitor’s advances. Pharmaceutical giant Pfizer (PFE) was shot down last week after making a $117 billion offer for AstraZeneca. Pfizer claims that was its final offer; apparently, it wasn’t enough. Sometimes, those disinterested companies are better off on their own. However, for every Facebook (FB) that correctly scoffed at a large figure (offered $1 billion, it’s worth north of $150 billion today), there are many companies that lived to regret turning down. Here are five companies whose owners really should have taken the money and run. Circuit City Circuit City is gone. The consumer electronics superstore chain filed for bankruptcy, liquidating all of its stores in 2009. It didn’t have to go out that way. There was no shortage of companies proposing to take over the once-vibrant retailer. It turned down private equity firms that wanted to pay $8 a share in 2003 and then $17 a share in 2005. Blockbuster Video — yes, that Blockbuster — even started to make buyout overtures in 2008. Blockbuster was hoping that teaming up with Circuit City would create “an $18 billion retail enterprise uniquely positioned for the convergence of media content and electronic devices.” It never panned out. Circuit City was out of business less than a year later. Take-Two Interactive (TTWO) Weeks before Take-Two Interactive’s “Grand Theft Auto IV” hit stores in 2008, Electronic Arts (EA) initiated a hostile takeover. It offered to pay $26 a share for Take-Two, but with the game expected to set industry sales records (which it eventually did), there was little reason

  • [By Leo Sun]

    Earlier this year, Superannuation estimated that Ubisoft’s production budget for Watch Dogs had hit $68 million. Although that would be significantly less than Activision Blizzard’s (NASDAQ: ATVI  ) $140 million budget for Destiny and Take-Two’s (NASDAQ: TTWO  ) $265 million budget for GTA V, it still represents a very confident investment for a new IP.

  • [By Maria Armental var popups = dojo.query(“.socialByline .popC”); popups.forEach]

    Take-Two Interactive Software Inc.(TTWO) swung to a fourth-quarter loss on a drop of nearly 35% in revenue, but topped analyst expectations and pointed to steady sales of new videogame titles including “Grand Theft Auto.”  Shares fell 3.4% to $19.93 premarket.

  • [By Jake L’Ecuyer]

    Take-Two Interactive Software (NASDAQ: TTWO) was down, falling 3.32 percent to $19.95 after the company issued a weak outlook. For the first quarter, the company expected an adjusted loss of $0.35 to $0.25 per share on revenue of $120 million to $125 million. However, analysts expected a loss of $0.12 per share on revenue of $209.6 million.

Best Supermarket Stocks To Own Right Now: Genesis Energy LP (GEL)

Genesis Energy, L.P. (Genesis) is a limited partnership focused on the midstream segment of the oil and gas industry in the Gulf Coast region of the United States, primarily Texas, Louisiana, Arkansas, Mississippi, Alabama, Florida and in the Gulf of Mexico. The Company has a portfolio of customers, operations and assets, including pipelines, refinery-related plants, storage tanks and terminals, barges and trucks. Genesis provides an integrated range of services to refineries, oil, natural gas and carbon dioxide (CO2) producers, industrial and commercial enterprises that use sodium hydrosulfide (NaHS) and caustic soda, and businesses that use CO2 and other industrial gases. The Company operates in three segments: Pipeline Transportation, Refinery Services, and Supply and Logistics. In August 2011, the Company acquired black oil barge transportation business of Florida Marine Transporters, Inc. In November 2011, it acquired a 90% interest in a 3,500 barrel per day refinery located in Converse County, Wyoming, including 300 miles of abandoned 3- 6 pipeline. On January 3, 2012, it acquired interests in several Gulf of Mexico crude oil pipeline systems, including its 28% interest in the Poseidon pipeline system, its 29% interest in the Odyssey pipeline system, and its 23% interest in the Eugene Island pipeline system. In August 2013, the Company announced that it has completed the acquisition of all the assets of the downstream transportation business of Hornbeck Offshore Transportation, LLC (Hornbeck).

Pipeline Transportation

The Company transports crude oil and carbon dioxide (CO2) for others for a fee in the Gulf Coast region of the United States through approximately 550 miles of pipeline. Its Pipeline Transportation segment owns and operates three crude oil common carrier pipelines and two CO2 pipelines. Its 235-mile Mississippi System provides shippers of crude oil in Mississippi indirect access to refineries, pipe lines, storage terminals and other crude oil infrastructure ! located in the Midwest. Its 100-mile Jay System originates in southern Alabama and the panhandle of Florida and provides crude oil shippers access to refineries, pipelines and storage near Mobile, Alabama. The Company’s 90-mile Texas System transports crude oil from West Columbia to several delivery points near Houston. Its crude oil pipeline systems include access to a total of approximately 0.7 million barrels of crude oil storage.

The Company’s Free State Pipeline is an 86-mile, 20 CO2 pipelines that extends from CO2 source fields near Jackson, Mississippi, to oil fields in eastern Mississippi. It has a twenty-year transportation services agreement (through 2028) related to the transportation of CO2 on its Free State Pipeline.

Refinery Services

Genesis provides services to eight refining operations located in Texas, Louisiana and Arkansas, which operates storage and transportation assets in relation to its business and sell NaHS and caustic soda to industrial and commercial companies. The refinery services involve processing refiner’s sulfur (sour) gas streams to remove the sulfur. The refinery services also include terminals and it utilizes railcars, ships, barges and trucks to transport product. Its contracts are long-term in nature and have an average remaining term of four years.

Supply and Logistics

The Company provides services to Gulf Coast oil and gas producers and refineries through a combination of purchasing, transporting, storing, blending and marketing of crude oil and refined products, primarily fuel oil. It has access to a range of more than 250 trucks, 350 trailers and 50 barges with 1.5 million barrels of terminal storage capacity in multiple locations along the Gulf Coast, as well as capacity associated with its three common carrier crude oil pipelines.

Advisors’ Opinion:

  • [By Dividends4Life]

    This week a few companies answered the call and rewarded their shareholders with higher cash dividends:

    Consolidated Edison Inc. (ED) engages in regulated electric, gas, and steam delivery businesses. January 16th the company increased its quarterly dividend 2.4% to $0.63 per share. The dividend is payable March 15, 2014, to stockholders of record on February 12, 2014. The yield based on the new payout is 4.7%.

    Cousins Properties Incorporated (CUZ), a real estate investment trust (REIT), owns, develops, and manages real estate portfolio, as well as performs certain real estate-related services. January 16th the company increased its quarterly dividend 66.7% to $0.075 per share. The dividend is payable February 24, 2014, to stockholders of record on February 10, 2014. The yield based on the new payout is 2.8%.

    Wisconsin Energy Corporation (WEC) generates and distributes electric energy, as well as distributes natural gas. The company operates in two segments, Utility Energy and Non-Utility Energy. January 16th the company increased its quarterly dividend 2% to $0.3900 per share. The dividend is payable March 1, 2014, to stockholders of record on February 14, 2014. The yield based on the new payout is 3.8%.

    BlackRock Inc. (BLK) is a publicly owned investment manager. The firm primarily provides its services to institutional, intermediary, and individual investors. January 16th the company increased its quarterly dividend 14.9% to $1.93 per share. The dividend is payable March 24, 2014, to stockholders of record on March 7, 2014. The yield based on the new payout is 2.4%.

    ONEOK Inc. (OKE) operates as a diversified energy company in the United States. January 15th the company increased its quarterly dividend 5.3% to $0.40 per share. The dividend is payable February 18, 2014, to stockholders of record on February 10, 2014. The yield based on the new payout is 2.5%.

    Omega Healthcare Investors Inc. (OHI) is a real es

  • [By Aimee Duffy]

    Distributions are incredibly important to master limited partnerships — they are the reason many investors buy in, and ultimately what drive the market performance for this asset class. As news of distribution increases trickle in for the third quarter, Fool.com contributor Aimee Duffy takes a look at the payouts from Genesis Energy (NYSE: GEL  ) , Plains All American Pipeline (NYSE: PAA  ) , and Memorial Production Partners (NASDAQ: MEMP  ) , as all three MLPs are leading the way with the biggest distribution increases.

  • [By Marc Bastow]

    Midstream oil and gas MLP Genesis Energy (GEL) raised its quarterly distribution 2.5% to 52.25 cents per share, payable Nov. 14 to unitholders of record as of Nov. 1.
    GEL Dividend Yield: 4.25%

  • [By Matt DiLallo]

    Genesis Energy (NYSE: GEL  )
    The final stock to get on your dividend watchlist is Genesis Energy. The company’s business is split between pipeline transportation, refinery services, and supply and logistics, as you can see on the slide below. In addition to the assets it already has on the books, Genesis has a number of projects in the pipeline to drive future growth. Genesis estimates that these projects will enable it to provide distribution growth to investors in the low double digits well into the future. Genesis has quite the history to back those estimates up as the company has 31 consecutive quarters of distribution increases, including 26 which were more than 10%. That’s what makes this dividend-paying stock one to watch.